✦ LIBER ✦

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

✍ Scribed by Dominique Larrey; Ansgar W. Lohse; Victor de Ledinghen; Christian Trepo; Tilman Gerlach; Jean-Pierre Zarski; Albert Tran; Philippe Mathurin; Robert Thimme; Keikawus Arastéh; Christian Trautwein; Andreas Cerny; Nektarios Dikopoulos; Marcus Schuchmann; Markus H. Heim; Guido Gerken; Jerry O. Stern; Katherine Wu; Nasri Abdallah; Birgit Girlich; Joseph Scherer; Frank Berger; Martin Marquis; George Kukolj; Wulf Böcher; Jürgen Steffgen

Book ID: 116652740
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 857 KB
Volume: 57
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2012.02.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2007 4 WEEK THERAPY WITH THE NON-NUCLEOS

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

✍ Larrey, D.; Lohse, A.; de Ledinghen, V.; Trepo, C.; Gerlach, T.; Zarski, J.-P.; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 54 KB

1163 A PHASE 2A STUDY OF BMS-791325, AN

1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

✍ Tatum, H.; Thuluvath, P.; Lawitz, E.; Martorell, C.T.; Demicco, M.; Cohen, S.; R 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

✍ Sulkowski, M.; Bourliere, M.; Bronowicki, J.-P.; Streinu-Cercel, A.; Preotescu, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

A Double-blind, randomized, placebo-cont

A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected

✍ Gardner, Stephen; Cutrell, Amy; Elko-Simms, Cindy; Adkison, Kimberly; Hamatake, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB